
Hematology-Oncologyrisk stratificationprognosis
Soluble BCMA as a Key Biomarker Defining Tumor Phenotypes and Prognosis in Newly Diagnosed Multiple Myeloma
By MedXY|Sep 27, 2026
Soluble BCMA levels in newly diagnosed multiple myeloma patients reveal distinct tumor phenotypes and predict prognosis more strongly than tumor volume, enabling improved risk stratification and clinical decision-making.